TrialPloS one2015

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.

Jan Pander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.